Evidence map›Paper›PMID 40426298›Full record

ArticleEuropean journal of immunology2025

Adaptive NKG2C

Mohamad Basem Alkassab, Fareeha Ajmal Shaikh, Caroline Hamm, Mir Munir A Rahim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mohamad Basem AlkassabDepartment of Biomedical Sciences, University of Windsor, Windsor, Ontario, Canada.
Fareeha Ajmal ShaikhDepartment of Biomedical Sciences, University of Windsor, Windsor, Ontario, Canada.
Caroline HammDepartment of Biomedical Sciences, University of Windsor, Windsor, Ontario, Canada.
Mir Munir A RahimDepartment of Biomedical Sciences, University of Windsor, Windsor, Ontario, Canada.ORCID 0000-0002-4622-1082

Funding

Katelyn Bedard Bone Marrow AssociationWindsor Cancer Centre Foundation Seeds4Hope Grant
6 · The paper itself

Abstract

The impact of cytomegalovirus (CMV) infection in shaping natural killer (NK) cell receptor (NKR) repertoire highlights the importance of NKRs in immunity against CMV. NKR-P1A (CD161) is an inhibitory NKR, whose expression is lost during CMV infection, but its role in NK cell responses during CMV infection is not known. Here, we show selective expansion of adaptive NKG2C

Indexed as

CytomegalovirusCytomegalovirus InfectionsKiller Cells, NaturalNK Cell Lectin-Like Receptor Subfamily ANK Cell Lectin-Like Receptor Subfamily CAdultFemaleHumansLymphocyte ActivationMaleMiddle AgedKLRC2 protein, humanNK Cell Lectin-Like Receptor Subfamily ANK Cell Lectin-Like Receptor Subfamily CCD161cytomegalovirusinhibitory receptorNK cellNKR‐P1A

Identifiers

PMID40426298
PMCPMC12117011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.